'First' stem cell treatment approved in Canada
This article was originally published in Clinica
Executive Summary
Osiris Therapeutics' Prochymal (remestemcel-L) for treating acute graft-vs-host disease (GvHD) has become the world's first manufactured stem cell therapy to win regulatory approval, claims the firm. Health Canada has approved the product for managing acute GvHD in children who fail to respond to steroids.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.